

# **Antihyperlipidemic Drugs Market Report by Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Stores, Online Retailers), and Region 2024-2032**

<https://marketpublishers.com/r/A6D613BFAE60EN.html>

Date: July 2024

Pages: 136

Price: US\$ 3,899.00 (Single User License)

ID: A6D613BFAE60EN

## **Abstracts**

The global antihyperlipidemic drugs market size reached US\$ 12.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 18.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

### **Antihyperlipidemic Drugs Market Trends:**

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause

of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

#### Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and distribution channel.

#### Breakup by Drug Class:

- Statins
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- PCSK9 Inhibitors
- Combination
- Others

#### Breakup by Route of Administration:

- Oral
- Intravenous

#### Breakup by Distribution Channel:

- Hospital Pharmacies
- Retail Stores
- Online Retailers

## Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

## Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

## Key Questions Answered in This Report

1. What was the size of the global antihyperlipidemic drugs market in 2023?
2. What is the expected growth rate of the global antihyperlipidemic drugs market during 2024-2032?
3. What are the key factors driving the global antihyperlipidemic drugs market?
4. What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?

5. What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
6. What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
7. What are the key regions in the global antihyperlipidemic drugs market?
8. Who are the key players/companies in the global antihyperlipidemic drugs market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 INTRODUCTION**

- 4.1 Overview
- 4.2 Key Industry Trends

### **5 GLOBAL ANTIHYPERLIPIDEMIC DRUGS MARKET**

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

### **6 MARKET BREAKUP BY DRUG CLASS**

- 6.1 Statins
  - 6.1.1 Market Trends
  - 6.1.2 Market Forecast
- 6.2 Bile Acid Sequestrants
  - 6.2.1 Market Trends
  - 6.2.2 Market Forecast
- 6.3 Cholesterol Absorption Inhibitors

- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Fibrin Acid Derivatives
  - 6.4.1 Market Trends
  - 6.4.2 Market Forecast
- 6.5 PCSK9 Inhibitors
  - 6.5.1 Market Trends
  - 6.5.2 Market Forecast
- 6.6 Combination
  - 6.6.1 Market Trends
  - 6.6.2 Market Forecast
- 6.7 Others
  - 6.7.1 Market Trends
  - 6.7.2 Market Forecast

## **7 MARKET BREAKUP BY ROUTE OF ADMINISTRATION**

- 7.1 Oral
  - 7.1.1 Market Trends
  - 7.1.2 Market Forecast
- 7.2 Intravenous
  - 7.2.1 Market Trends
  - 7.2.2 Market Forecast

## **8 MARKET BREAKUP BY DISTRIBUTION CHANNEL**

- 8.1 Hospital Pharmacies
  - 8.1.1 Market Trends
  - 8.1.2 Market Forecast
- 8.2 Retail Stores
  - 8.2.1 Market Trends
  - 8.2.2 Market Forecast
- 8.3 Online Retailers
  - 8.3.1 Market Trends
  - 8.3.2 Market Forecast

## **9 MARKET BREAKUP BY REGION**

- 9.1 North America

- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
  - 9.2.1 China
    - 9.2.1.1 Market Trends
    - 9.2.1.2 Market Forecast
  - 9.2.2 Japan
    - 9.2.2.1 Market Trends
    - 9.2.2.2 Market Forecast
  - 9.2.3 India
    - 9.2.3.1 Market Trends
    - 9.2.3.2 Market Forecast
  - 9.2.4 South Korea
    - 9.2.4.1 Market Trends
    - 9.2.4.2 Market Forecast
  - 9.2.5 Australia
    - 9.2.5.1 Market Trends
    - 9.2.5.2 Market Forecast
  - 9.2.6 Indonesia
    - 9.2.6.1 Market Trends
    - 9.2.6.2 Market Forecast
  - 9.2.7 Others
    - 9.2.7.1 Market Trends
    - 9.2.7.2 Market Forecast
- 9.3 Europe
  - 9.3.1 Germany
    - 9.3.1.1 Market Trends
    - 9.3.1.2 Market Forecast
  - 9.3.2 France
    - 9.3.2.1 Market Trends
    - 9.3.2.2 Market Forecast
  - 9.3.3 United Kingdom
    - 9.3.3.1 Market Trends
    - 9.3.3.2 Market Forecast
  - 9.3.4 Italy

- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
- 9.4 Latin America
  - 9.4.1 Brazil
    - 9.4.1.1 Market Trends
    - 9.4.1.2 Market Forecast
  - 9.4.2 Mexico
    - 9.4.2.1 Market Trends
    - 9.4.2.2 Market Forecast
  - 9.4.3 Others
    - 9.4.3.1 Market Trends
    - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
  - 9.5.1 Market Trends
  - 9.5.2 Market Breakup by Country
  - 9.5.3 Market Forecast

## **10 SWOT ANALYSIS**

- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats

## **11 VALUE CHAIN ANALYSIS**

## **12 PORTERS FIVE FORCES ANALYSIS**

- 12.1 Overview



- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes

## **13 PRICE ANALYSIS**

## **14 COMPETITIVE LANDSCAPE**

- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
  - 14.3.1 Amgen Inc.
    - 14.3.1.1 Company Overview
    - 14.3.1.2 Product Portfolio
    - 14.3.1.3 Financials
  - 14.3.2 AstraZeneca plc
    - 14.3.2.1 Company Overview
    - 14.3.2.2 Product Portfolio
    - 14.3.2.3 Financials
    - 14.3.2.4 SWOT Analysis
  - 14.3.3 Daiichi Sankyo Company Limited
    - 14.3.3.1 Company Overview
    - 14.3.3.2 Product Portfolio
    - 14.3.3.3 Financials
    - 14.3.3.4 SWOT Analysis
  - 14.3.4 Merck & Co. Inc.
    - 14.3.4.1 Company Overview
    - 14.3.4.2 Product Portfolio
    - 14.3.4.3 Financials
  - 14.3.5 Novartis AG
    - 14.3.5.1 Company Overview
    - 14.3.5.2 Product Portfolio
    - 14.3.5.3 Financials
    - 14.3.5.4 SWOT Analysis
  - 14.3.6 Pfizer Inc.
    - 14.3.6.1 Company Overview
    - 14.3.6.2 Product Portfolio

14.3.6.3 Financials

14.3.7 Sanofi S.A

14.3.7.1 Company Overview

14.3.7.2 Product Portfolio

14.3.7.3 Financials

## I would like to order

Product name: Antihyperlipidemic Drugs Market Report by Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Stores, Online Retailers), and Region 2024-2032

Product link: <https://marketpublishers.com/r/A6D613BFAE60EN.html>

Price: US\$ 3,899.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A6D613BFAE60EN.html>